JPH09503393A - 二本鎖dnaの核酸類似体による誘導転写 - Google Patents
二本鎖dnaの核酸類似体による誘導転写Info
- Publication number
- JPH09503393A JPH09503393A JP7514828A JP51482895A JPH09503393A JP H09503393 A JPH09503393 A JP H09503393A JP 7514828 A JP7514828 A JP 7514828A JP 51482895 A JP51482895 A JP 51482895A JP H09503393 A JPH09503393 A JP H09503393A
- Authority
- JP
- Japan
- Prior art keywords
- group
- nucleic acid
- dna
- rna
- transcription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004414 DNA Proteins 0.000 title claims abstract description 72
- 102000053602 DNA Human genes 0.000 title claims abstract description 21
- 150000007523 nucleic acids Chemical class 0.000 title claims description 51
- 102000039446 nucleic acids Human genes 0.000 title claims description 47
- 108020004707 nucleic acids Proteins 0.000 title claims description 47
- 238000013518 transcription Methods 0.000 title claims description 44
- 230000035897 transcription Effects 0.000 title claims description 43
- 239000002253 acid Substances 0.000 claims abstract description 24
- 108700009124 Transcription Initiation Site Proteins 0.000 claims abstract description 10
- -1 nucleoside triphosphate Chemical class 0.000 claims abstract description 8
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims abstract description 7
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims abstract description 7
- 230000001419 dependent effect Effects 0.000 claims abstract description 6
- 239000002777 nucleoside Substances 0.000 claims abstract description 6
- 239000001226 triphosphate Substances 0.000 claims abstract description 6
- 235000011178 triphosphate Nutrition 0.000 claims abstract description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 55
- 230000000295 complement effect Effects 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 239000002853 nucleic acid probe Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 238000002405 diagnostic procedure Methods 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000012625 DNA intercalator Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- 239000001177 diphosphate Substances 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 238000003505 heat denaturation Methods 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 125000001010 sulfinic acid amide group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 150000001371 alpha-amino acids Chemical class 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 238000009396 hybridization Methods 0.000 abstract description 5
- 238000006073 displacement reaction Methods 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 230000005026 transcription initiation Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 2
- 101710124361 Arylamine N-acetyltransferase 2 Proteins 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000002112 DNA intercalation Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010025076 Holoenzymes Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- OIPMQULDKWSNGX-UHFFFAOYSA-N bis[[ethoxy(oxo)phosphaniumyl]oxy]alumanyloxy-ethoxy-oxophosphanium Chemical compound [Al+3].CCO[P+]([O-])=O.CCO[P+]([O-])=O.CCO[P+]([O-])=O OIPMQULDKWSNGX-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.二本鎖DNA鋳型からRNAを転写する方法であって、該鋳型を所望の転写 開始部位で、該DNAと転写開始部位を形成することができる1個又は2個以上 のオリゴ核酸類似体(oligo-nucleic acid analogues)とハイブリダイズさせる ことにより複合体を形成させること、及び該複合体をヌクレオシド三リン酸の存 在下にDNA依存性RNAポリメラーゼの作用に付することを含んでなる方法。 2.該オリゴ核酸類似体の1対が、該DNAの同一又は異なる鎖の上の隣接位置 又は隔てられた位置にハイブリダイズしているものである、請求項1記載の方法 。 3.該1対のオリゴ核酸が該DNAの0から10塩基対だけ隔てられているもの である、請求項2記載の方法。 4.該オリゴ核酸類似体又はその各々が10から20の核酸類似体ユニット長を 有するものである、請求項1〜3いずれか記載の方法。 5.下記の工程を含むRNAポリメラーゼによる転写のための基質に1本鎖核酸 を変換する方法、 −核酸を特異的結合配列を含む2本鎖DNAに酵素的に変換する工程、 −該ハイブリッドを特異的結合配列に相補的な核酸塩基配列を含む核酸類似体と ハイブリダイズさせる工程、及び −該ハイブリッドをRNAポリメラーゼの作用に付する工程。 6.転写に対するブロックが該転写において等しい長さの転写物が得られるよう に所望の該開始部位の下流の位置に置かれるものである、又は転写物の長さが該 開始部位の下流の選択された位置で鋳型を切断することにより制御されるもので ある、請求項1〜5いずれか記載の方法。 7.該ブロックが、転写を阻止することができるオリゴ核酸類似体を該DNAに ハイブリダイズさせることにより作成するものである、請求項5記載の方法。 8.核酸類似体がアミド、チオアミド、スルフィンアミド、又はスルホンアミド バックボーンを有するものである、請求項1〜7いずれか記載の方法。 9.使用される該核酸類似体が、ペプチド核酸であって、該バックボーンがポリ アミドバックボーンであり、該リガンドのそれぞれが該バックボーン中のアザ窒 素原子に直接的又は間接的に結合しており、そして窒素原子を持つ該リガンドが 主として該バックボーン中で相互に4〜8介入原子だけ隔てられているものであ る、請求項1〜7いずれか記載の方法。 10.使用される該核酸類似体が、相補的配列の核酸にハイブリダイズし、該類 似体及び該核酸に配列において相当する通常のデオキシリボヌクレオチド間に形 成されるハイブリッドよりも熱変性に対してより安定なハイブリッドを形成する ことができるものである、請求項1〜9いずれか記載の方法。 11.使用される核酸類似体が、その一方の鎖が該類似体に相補的な配列を有す る二本鎖核酸にハイブリダイズして該一方の鎖から他方の鎖を置換することがで きるものである、請求項1〜10いずれか記載の方法。 12.該核酸類似体が一般式1の化合物を含んでなるものである、請求項11記 載の方法、 式中、nは少なくとも2であり、L1〜Lnはそれぞれ独立に、水素、水酸基、( C1〜C4)アルカノイル基、天然に 生ずる核酸塩基類、天然に生じない核酸塩基類、芳香族部分、DNAインターカ ーレーター類、核酸塩基結合基、複素環部分、及びレポーターリガンド類からな る群より選択されるものであり、 C1〜Cnのそれぞれは(CR6R7)yであり、ここでR6は水素であり、R7は天 然に生ずるαアミノ酸類の側鎖からなる群より選択されるものであり、又はR6 とR7は独立に水素、(C2〜C6)アルキル基、アリール基、アラルキル基、ヘ テロアリール基、水酸基、(C1〜C6)アルコキシ基、(C1〜C6)アルキルチ オ基、NR3R4及びSR5からなる群より選択されるものであり、ここでR3とR4 は以下に定義され、R5は水素、(C1〜C6)アルキル基、水酸基、アルコキシ 基、又はアルキルチオ置換(C1〜C6)アルキル基であり、又はR6とR7は一緒 になって脂環系又は複素環系を作り、 D1〜Dnはそれぞれ、(CR6R7)zであり、ここでR6とR7は上記のように定 義される、 y及びzはそれぞれゼロ又は1〜10の整数であり、y+zの和は2〜10であ り、 G1〜Gn-1はそれぞれ、−NR3CO−、−NR3C5−、−NR3SO−、又は− NR3SO2−でありいずれの方向でもよく、ここでR3は以下に定義される、 A1〜An及びB2〜Bnはそれぞれ以下のものから選択される、 (a)Aは式(IIa)、(IIb)、(IIc)又は(IId)の群であり 、かつBはN又はR3N+であり、又は (b)Aは式(IId)の群であり、かつBはCHであり、 式中、XはO、S、Se、NR3、CH2又はC(CH3)2であり、 Yは単結合、O、S又はNR4であり、 pとqはそれぞれゼロ又は1〜5の整数であり、p+qの和は10以下であり、 rとsはそれぞれゼロ又は1〜5の整数であり、r+sの和は10以下であり、 R1とR2はそれぞれ独立に水素、水酸基−,アルコキシ基−,又はアルキルチオ 基−で置換されていてもよい(C1〜C4)アルキル基、、水酸基、アルコキシ基 、アルキルチオ基、アミノ基及びハロゲンからなる群より選択されるものであり 、そして R3及びR4はそれぞれ独立に水素、(C1〜C4)アルキ ル基、水酸基−,アルコキシ基−,アルキルチオ基−置換(C1〜C4)アルキル 基、水酸基、アルコキシ基、アルキルチオ基及びアミノ基からなる群から選択さ れるものであり、 Qは−CO2H、−CONR’R”、−SO3H又は−SO2NR’R”、又は− CO2H又は−SO3Hの活性誘導体、及び Iは−NR''' R''''又は−NR''' C(O)R''''であり、ここでR’、R'' 、R''' 及びR''''は、独立に水素、アルキル基、アミノ保護基、レポーターリ ガンド、インターカーレーター、キレーター、ペプチド、タンパク質、炭水化物 、リピド、ステロイド、ヌクレオシド、ヌクレオチド、ヌクレオチド二リン酸、 ヌクレオチド三リン酸、オリゴヌクレオチド、オリゴヌクレオシド、及び可溶性 及び不溶性ポリマーからなる群より選択されるものである。 13.該核酸類似体が一般式III 、IV、又はVの化合物を含むものである、請求 項12記載の方法、 式中、Lはそれぞれ独立に水素、フェニル、複素環部分、天然に生ずる核酸塩基 、及び天然に生じない核酸塩基からなる群より選択されるものであり、R3はそ れぞれ上に定義したとおりであり、 R7はそれぞれ独立に水素及び天然に生ずるαアミノ酸の側鎖からなる群より選 択されるものであり、 nは1より大きな整数であり、 各k、l及びmは独立にゼロ又は1〜5の整数であり、 pはそれぞれゼロ又は1であり、 RhはOH、NH2又は−NHLysNH2であり、そして R’はH又はCOCH3である。 14.上に記載した請求項のいずれか1項に従ってRNA作成のための転写を行 い、そして該RNA生成を検出することを含んでなる、請求項1〜13いずれか 記載の診断方法。 15.該RNAが相補的配列の核酸プローブに捕捉され、そして検出可能な標識 を持つ核酸プローブにも結合させるものである、請求項11記載の診断方法。 16.DNA鋳型分子のそれぞれから複数のRNAコピーを作成する方法におい て、請求項1〜13いずれか記載の方法により、DNAからRNA転写物を調製 することを含んでなる核酸増幅方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9324245.1 | 1993-11-25 | ||
| GB9324245A GB2284209A (en) | 1993-11-25 | 1993-11-25 | Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template |
| PCT/EP1994/003858 WO1995014789A1 (en) | 1993-11-25 | 1994-11-22 | Nucleic acid analogue induced transcription of double stranded dna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09503393A true JPH09503393A (ja) | 1997-04-08 |
| JP3143475B2 JP3143475B2 (ja) | 2001-03-07 |
Family
ID=10745684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP07514828A Expired - Fee Related JP3143475B2 (ja) | 1993-11-25 | 1994-11-22 | 二本鎖dnaの核酸類似体による誘導転写 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5837459A (ja) |
| EP (1) | EP0730664B1 (ja) |
| JP (1) | JP3143475B2 (ja) |
| AT (1) | ATE176932T1 (ja) |
| CA (1) | CA2176746C (ja) |
| DE (1) | DE69416692T2 (ja) |
| DK (1) | DK0730664T3 (ja) |
| ES (1) | ES2133709T3 (ja) |
| GB (1) | GB2284209A (ja) |
| WO (1) | WO1995014789A1 (ja) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770738B1 (en) * | 1992-05-22 | 2004-08-03 | Isis Pharmaceuticals, Inc. | Higher order structure and binding of peptide nucleic acids |
| CA2140081C (en) * | 1994-01-13 | 2008-04-01 | Dean L. Engelhardt | Process, construct and conjugate for producing multiple nucleic acid copies |
| WO1997014793A1 (en) * | 1995-10-20 | 1997-04-24 | Trustees Of Boston University | Nucleic acid clamps |
| US6617422B1 (en) | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
| US6723560B2 (en) | 1998-10-08 | 2004-04-20 | Mayo Foundation For Medical Education And Research | Using polyamide nucleic acid oligomers to engender a biological response |
| US6989270B1 (en) | 1997-10-17 | 2006-01-24 | Mayo Foundation For Medical Education And Research | Using polyamide nucleic acid oligomers to engender a biological response |
| AU3671099A (en) | 1998-04-29 | 1999-11-16 | Trustees Of Boston University | Methods and compositions pertaining to pd-loops |
| US7981599B1 (en) | 1998-07-31 | 2011-07-19 | Boston Probes, Inc. | Non-nucleic acid probes, probe sets, methods and kits pertaining to the detection of individual human chromosomes X, Y, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18 and 20 as 13/21 as a pair |
| US6962906B2 (en) * | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| AU2001247414A1 (en) | 2000-03-14 | 2001-09-24 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| US20040014644A1 (en) * | 2000-03-14 | 2004-01-22 | Vladimir Efimov | Oligonucleotide analogues and methods of use for modulating gene expression |
| EP1349958B1 (en) | 2000-09-26 | 2009-06-03 | Boston Probes, Inc. | Probes, probe sets, methods and kits pertaining to the detection, identification and/or enumeration of bacteria |
| WO2002031166A2 (en) * | 2000-10-13 | 2002-04-18 | Crosslink Genetics Corporation | Artificial transcriptional factors and methods of use |
| WO2002057493A2 (en) * | 2000-12-15 | 2002-07-25 | Boston Probes, Inc. | Methods for determining organisms |
| US7256275B2 (en) * | 2001-03-09 | 2007-08-14 | Boston Probes, Inc. | Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation |
| US8026051B2 (en) | 2001-05-18 | 2011-09-27 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the detection of Candida |
| US20030129626A1 (en) * | 2001-09-24 | 2003-07-10 | Nielsen Kirsten Vang | Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid |
| US7045319B2 (en) * | 2001-10-30 | 2006-05-16 | Ribomed Biotechnologies, Inc. | Molecular detection systems utilizing reiterative oligonucleotide synthesis |
| WO2003080857A2 (en) * | 2002-03-21 | 2003-10-02 | Boston Probes,Inc. | Pna oligomers, oligomers sets, methods and kits pertaining to the detection of bacillus anthracis |
| US20030211509A1 (en) * | 2002-03-26 | 2003-11-13 | Wiley Steven R. | TNF-delta ligand and uses thereof |
| JP2006507798A (ja) * | 2002-05-17 | 2006-03-09 | アプレラ コーポレイション | Listeriaの決定に関するPNAプローブ、プローブセット、方法およびキット |
| DE60330182D1 (de) | 2002-09-08 | 2009-12-31 | Applera Corp | Festphasengebundene PNA-Dimere und deren Synthese |
| WO2004048594A2 (en) * | 2002-11-21 | 2004-06-10 | Epicentre Technologies | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences |
| US20040259132A1 (en) * | 2002-11-22 | 2004-12-23 | Henrik Stender | Peptide nucleic acid probes for analysis of pseudomonas (sensu stricto) |
| KR20070012779A (ko) * | 2003-10-29 | 2007-01-29 | 리보메드 바이오테그놀로지스 인코포레이티드 | 반복적 올리고뉴클레오티드 합성을 위한 조성물, 방법 및검출 기법 |
| US7306916B2 (en) * | 2004-05-04 | 2007-12-11 | Dako Denmark A/S | Methods for detecting chromosome aberrations |
| WO2007044031A2 (en) * | 2004-12-06 | 2007-04-19 | Bioveris Corporation | Methods and compositions for detecting bacillus anthracis |
| WO2006081426A2 (en) * | 2005-01-28 | 2006-08-03 | Applera Corporation | Compositions and methods for terminating a sequencing reaction at a specific location in a target dna template |
| CN101495647B (zh) | 2005-06-02 | 2014-12-17 | 阿德万德克斯公司 | 用于微生物分析的肽核酸探针 |
| DE602006020577D1 (de) | 2005-07-01 | 2011-04-21 | Dako Denmark As | Monomere und polymere linker zur konjugierung von biologischen molekülen und anderen stoffen |
| AU2007339793A1 (en) * | 2006-12-29 | 2008-07-10 | Applied Biosystems, Llc | Systems and methods for detecting nucleic acids |
| WO2008083261A1 (en) * | 2006-12-29 | 2008-07-10 | Applera Corporation | Systems and methods for detecting nucleic acids |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| EP2297346B1 (en) | 2008-05-15 | 2015-04-15 | Ribomed Biotechnologies, Inc. | METHODS AND REAGENTS FOR DETECTING CpG METHYLATION WITH A METHYL CpG BINDING PROTEIN (MBP) |
| JP5588970B2 (ja) | 2008-05-27 | 2014-09-10 | ダコ・デンマーク・エー/エス | ハイブリダイゼーション組成物及び方法 |
| US8211644B2 (en) * | 2008-07-13 | 2012-07-03 | Ribomed Biotechnologies, Inc. | Molecular beacon-based methods for detection of targets using abscription |
| US9303287B2 (en) | 2009-02-26 | 2016-04-05 | Dako Denmark A/S | Compositions and methods for RNA hybridization applications |
| AU2010225937B2 (en) | 2009-03-15 | 2014-09-18 | Ribomed Biotechnologies, Inc. | Abscription based molecular detection |
| EP2507391B1 (en) | 2009-12-02 | 2016-08-17 | Dako Denmark A/S | Compositions and methods for performing hybridizations with no denaturation |
| US9404160B2 (en) | 2009-12-22 | 2016-08-02 | Becton, Dickinson And Company | Methods for the detection of microorganisms |
| US10662465B2 (en) | 2011-09-30 | 2020-05-26 | Agilent Technologies, Inc. | Hybridization compositions and methods using formamide |
| US11118226B2 (en) | 2011-10-21 | 2021-09-14 | Agilent Technologies, Inc. | Hybridization compositions and methods |
| WO2014033314A1 (en) | 2012-09-03 | 2014-03-06 | Uab Bioseka | Antisense oligonucleotide targeting bacterial glucosyltransferases |
| WO2014093291A1 (en) | 2012-12-10 | 2014-06-19 | Advandx, Inc. | Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest |
| US9909123B2 (en) | 2013-03-15 | 2018-03-06 | Techulon Inc. | Antisense molecules for treatment of Staphylococcus aureus infection |
| EP2968603B1 (en) | 2013-03-15 | 2020-06-24 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
| LT6214B (lt) | 2013-10-07 | 2015-08-25 | Uab "Bioseka" | Priešprasminiai oligonukleotidai aterosklerozės ir kardiovaskulinių infekcijų prevencijai |
| JP6640079B2 (ja) | 2013-10-16 | 2020-02-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 小容積の粒子を調製するためのデバイス及び方法 |
| WO2016138175A1 (en) | 2015-02-24 | 2016-09-01 | The University Of British Columbia | Continuous flow microfluidic system |
| EP3400097B1 (en) | 2016-01-06 | 2021-01-27 | The University Of British Columbia | Bifurcating mixers and methods of their use and manufacture |
| WO2018064755A1 (en) | 2016-10-03 | 2018-04-12 | Precision Nanosystems Inc. | Compositions for transfecting resistant cell types |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340807C (en) * | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5130238A (en) * | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| IE65771B1 (en) * | 1990-01-25 | 1995-11-15 | Zeneca Ltd | Amplification of nucleotide sequences using vectorette units |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| GB9211979D0 (en) * | 1992-06-05 | 1992-07-15 | Buchard Ole | Uses of nucleic acid analogues |
-
1993
- 1993-11-25 GB GB9324245A patent/GB2284209A/en not_active Withdrawn
-
1994
- 1994-11-22 ES ES95901410T patent/ES2133709T3/es not_active Expired - Lifetime
- 1994-11-22 DK DK95901410T patent/DK0730664T3/da active
- 1994-11-22 EP EP95901410A patent/EP0730664B1/en not_active Expired - Lifetime
- 1994-11-22 CA CA002176746A patent/CA2176746C/en not_active Expired - Lifetime
- 1994-11-22 AT AT95901410T patent/ATE176932T1/de not_active IP Right Cessation
- 1994-11-22 JP JP07514828A patent/JP3143475B2/ja not_active Expired - Fee Related
- 1994-11-22 DE DE69416692T patent/DE69416692T2/de not_active Expired - Fee Related
- 1994-11-22 WO PCT/EP1994/003858 patent/WO1995014789A1/en not_active Ceased
-
1996
- 1996-05-24 US US08/653,605 patent/US5837459A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995014789A1 (en) | 1995-06-01 |
| ES2133709T3 (es) | 1999-09-16 |
| JP3143475B2 (ja) | 2001-03-07 |
| DE69416692D1 (de) | 1999-04-01 |
| EP0730664A1 (en) | 1996-09-11 |
| DK0730664T3 (da) | 1999-09-27 |
| GB2284209A (en) | 1995-05-31 |
| GB2284209A8 (en) | 1995-09-25 |
| CA2176746C (en) | 2000-08-08 |
| ATE176932T1 (de) | 1999-03-15 |
| US5837459A (en) | 1998-11-17 |
| EP0730664B1 (en) | 1999-02-24 |
| DE69416692T2 (de) | 1999-08-05 |
| GB9324245D0 (en) | 1994-01-12 |
| CA2176746A1 (en) | 1995-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09503393A (ja) | 二本鎖dnaの核酸類似体による誘導転写 | |
| JP3061064B2 (ja) | 核酸増幅の阻害における核酸類似物の使用 | |
| Nishikura et al. | Substrate specificity of the dsRNA unwinding/modifying activity. | |
| JP3644976B2 (ja) | 核酸の増幅の改良法 | |
| Shabarova et al. | Chemical ligation of DNA: the first non-enzymatic assembly of a biologically active gene | |
| JP5795317B2 (ja) | 光を用いた核酸の増幅抑制方法および高感度な選択的核酸増幅方法 | |
| DE602005026730D1 (de) | Einfach-Primernukleinsäuren-Erweiterungsverfahren | |
| JP2008516584A (ja) | 新規ホットスタート核酸増幅法 | |
| JPH11236396A (ja) | ペプチド核酸の高次構造および結合 | |
| Ohbayashi et al. | Expansion of repertoire of modified DNAs prepared by PCR using KOD Dash DNA polymerase | |
| JP2002507128A (ja) | サイクリングプローブ反応における使用のための添加物 | |
| JP2009000044A (ja) | 核酸増幅法 | |
| Sekiya et al. | The nucleotide sequence in the promoter region of the gene for an Escherichia coli tyrosine transfer ribonucleic acid. | |
| JP6612883B2 (ja) | 相補的塩基配列ないしはミス−マッチされた塩基を含む相補的な塩基配列と連結されたpcrプライマー及びそれを用いた核酸増幅方法 | |
| JP3084733B2 (ja) | 標的核酸の増幅方法、検出方法およびそのためのキット | |
| Wilhelm et al. | Polypurine tract formation by Ty1 RNase H | |
| Brossalina et al. | Sequence-specific alkylation of dsDNA with derivatives of pyrimidine oligonucleotides conjugated to 2-chloroethylamine groups | |
| CN114144525A (zh) | 嵌合分子、药物组合物、靶核酸的切割方法以及靶核酸切割用或诊断用试剂盒 | |
| JPH0767646A (ja) | 試料中に含まれる特定rna配列を鋳型とする核酸配列の増幅方法 | |
| JPWO1999009213A1 (ja) | Dna増幅方法及びそのキット | |
| Sastry et al. | The influence of RNA and DNA template structures during transcript elongation by RNA polymerases | |
| Artzi et al. | Ribonuclease H activity during initiation of reverse transcription using tRNALys/RNA primer/template of human immunodeficiency virus | |
| Parker | Mitomycin C-induced bidirectional transcription from the colicin E1 promoter region in plasmid ColE1 | |
| US20230027474A1 (en) | Blocking-type chain polymerization amplification reaction based in vitro fast synthesis of medium and high-copy dna repetitive sequence | |
| Nielsen et al. | RING-CLOSING METATHESIS REACTIONS IN NUCLEIC ACID CHEMISTRY—CYCLIC DINUCLEOTIDES FOR TARGETING SECONDARY NUCLEIC ACID STRUCTURES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081222 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081222 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081222 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081222 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |